Music Therapy Preferences Among Breast Cancer Patients Undergoing Perioperative Chemotherapy: From Qualitative Insight to Quantitative Evidence

Music Therapy Preferences Among Breast Cancer Patients Undergoing Perioperative Chemotherapy: From Qualitative Insight to Quantitative Evidence | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Music Therapy Preferences Among Breast Cancer Patients Undergoing Perioperative Chemotherapy: From Qualitative Insight to Quantitative Evidence Nanami Nakaya, Ami Yamasato, Mayu Kondo, Shigeki Okino, Atsuko Kitano, and 3 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-6695158/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 03 Sep, 2025 Read the published version in International Journal of Clinical Oncology → Version 1 posted 5 You are reading this latest preprint version Abstract Background : Patients with breast cancer (PWBC) have a high risk of developing psychological disorders, and interventions should be implemented with care. For music therapy (MT)interventions to be more effective among these patients, providing therapeutic programs tailored to their preferences is desirable. Given the limited research on the preferences for MT of PWBC undergoing chemotherapy, we had previously conducted a qualitative study to clarify their preferences, yielding the formation of related hypotheses. Building upon these hypotheses, the current quantitative study aimed to clarify the specific preferences regarding MT of PWBC, who are undergoing chemotherapy, in Japan. Methods : This quantitative study’s questionnaire was created based on the results of our prior qualitative study and completed by 300 PWBC undergoing perioperative chemotherapy. Results : (a) Of all participants, 80.9% wanted MT, and there was a relationship between preferred activity type and participants’ sociodemographic and clinical characteristics; (b) the expectations of participants regarding MT differed by preferred activity type; and (c) the participants’ preferences regarding the frequency, timing, duration, and cost of the MT intervention were constant regardless of the preferred activity type. Conclusions : As patients’ specific preferences have been clarified, we conclude that professionals may be more well-positioned and informed to devise more appropriate and effective MT programs to be incorporated into the treatment schedules of PWBC who are undergoing chemotherapy, with vital quality-of-life implications resulting. music therapy palliative care preference request breast cancer 1. Introduction The effectiveness of music therapy (MT) in patients with cancer has recently been reported, with meta-analyses and reviews conducted to clarify this effectiveness showing that such therapy and music-based interventions improve quality of life (QoL), anxiety, depression, and pain in patients with cancer [ 1 – 3 ]. These studies also illustrate that MT and music-based interventions for this population may be effective in various treatment situations (e.g., before and after tests and surgery, during chemotherapy, and during palliative care), regardless of cancer type. Furthermore, this therapy may be useful for alleviating physical problems (e.g., pain), low life quality, and psychological issues (e.g., depression and anxiety) caused by cancer and its treatment. Breast cancer is the most common cancer among women, accounting for 11.6% of all cancers worldwide [ 4 ]. Patients with breast cancer (PWBC) are also at high risk of developing psychological disorders, e.g., depression and anxiety [ 5 ], with a global depression prevalence among these patients of 32.2% [ 6 ]. Some studies have reported that receptive MT significantly improves symptoms of pain, depression, fatigue, and sleep disorders [ 7 – 9 ]. However, these studies often developed the MT protocol based on the music therapist’s experience rather than on a standardized format, considering participants, techniques, or duration of therapy. The consensus is that MT for patients with cancer should be tailored to the type of cancer afflicting the patient and their unique treatment situation (e.g., whether before or after tests and surgery or during chemotherapy and palliative care) [ 10 ]. However, limited research has examined patient preferences. One study reported that 88% of patients with cancer undergoing treatment for three months expressed positive opinions on MT [ 11 ]. Before the authors’ initial qualitative study [ 12 ], no studies in Japan had examined the preferences or opinions of patients with cancer regarding MT or the preferences of PWBC undergoing treatment or MT protocols. To address the gap in patient-informed MT design, we conducted a qualitative study to clarify the preferences of Japanese PWBC regarding MT during chemotherapy [ 12 ]. The results were classified into three categories: relationship to music, pain from treatment, and preferences for MT. The analysis showed that patients undergoing chemotherapy determine their MT preferences based on their own musical experiences and physical and psychological pain. Furthermore, subcategories were created for patients’ expectations regarding the content, frequency, duration, and cost—among other factors—of MT. An overview of the MT expectations of PWBC undergoing perioperative chemotherapy was presented. Subsequently, to determine whether the content of the authors’ prior qualitative research represents the opinions of most PWBC undergoing perioperative chemotherapy, a larger-scale quantitative study was deemed necessary. Thus, building on prior qualitative findings, this study aimed to quantitatively examine MT preferences—across dimensions such as activity type, timing, frequency, duration, cost, and therapeutic expectations—among PWBC undergoing perioperative chemotherapy in Japan. 2. Methods 2.1. Participants Participants were adults who 1) had been diagnosed with primary breast cancer and were undergoing or had undergone perioperative chemotherapy at University Hospital A or Hospital B, or 2) were involved in Breast Cancer Support Community C, had been diagnosed with primary breast cancer, and were undergoing or had undergone perioperative chemotherapy. All participants read the explanatory document and provided informed consent. The doctors in charge at University Hospital A and Hospital B recruited participants by distributing flyers to viable candidates. These candidates accessed and answered the questionnaire online using the URL and QR code provided on the flyer. Breast Cancer Support Community C was similarly asked to include the questionnaire URL and QR code in a recruitment-focused email and distribute it to potential participants. The questionnaire was developed using subcategories obtained from the prior qualitative study, with the corresponding codes used as multiple-choice options. It was validated by experts, including music therapists, psychiatrists, breast oncologists, and palliative care physicians. The application period spanned September 2021–November 2021. 2.2. Data collection The questionnaire was created based on the results of a qualitative study [ 12 ] conducted using Charmaz’s [ 13 ] constructivist grounded theory approach. The multiple-choice questionnaire collected data on respondents’ current age, age at diagnosis, marital status, educational level, occupation, current treatment status, and chemotherapy type, as well as their preferred MT format (group or IT), expectations, frequency, timing, duration, and cost. Data were collected online using Questant [ 14 ]—a self-administered questionnaire tool provided by Macromill, Inc. 2.3. Analysis Descriptive statistics were utilized to analyze the data collected using the questionnaire. Pearson’s chi-squared test and the Kruskal–Walis test were employed to investigate the relationship between participants’ sociodemographics, clinical characteristics, and preferred activity type, with p < 0.05 expressing statistical significance in both tests. A residual analysis was conducted for items with a significant difference in Pearson’s chi-squared test; for items with a significant difference in the Kruskal–Walis test (p < 0.05), the groups were compared. A Pearson’s chi-squared test (p < 0.05) was conducted to assess differences in expectations between group and IT when both were desired. Items with a significant difference underwent a residual analysis. SPSS version 26 was used for all statistical procedures. To uphold the findings’ reliability and validity, the research team (comprising psychiatrists, music therapists, breast oncology specialists, and musicology experts) met once a week to review data collection methods, share data, and confirm analysis methods and results. 3. Results 3.1. Participants’ sociodemographic and clinical characteristics The study included 300 participants aged 21–84 (M=52.2 years, SD=12.4), with an age at diagnosis of 20–77 (M=47.7 years, SD=11.9). Table 1 shows participants’ sociodemographic and clinical characteristics. 3.2. Factors associated with preferred activity type Regarding preferred activity type, 93 participants (31.0%) chose “group therapy” (GT), 88 (29.3%) “individual therapy” (IT), 61 (20.3%) “I want to receive both,” and 57 (19.0%) “I don’t want to receive either.” In total, 80.9% of participants expressed interest in receiving some form of MT. Among those preferring neither (multiple responses were allowed), 26.3% answered “because it is physically painful,” meaning they are in too much pain to consider receiving therapy, and 22.8% responded “because it is not psychologically painful” and therefore do not need any pain-relieving therapies. Analyses using participants’ current age revealed that people preferring GT were older than those preferring IT (95% CI, 2.6852–11.5480) and older than those preferring both (95% CI, 5.4864–15.3498). People preferring IT were younger than those preferring GT and younger than those preferring neither (95% CI, -14.243–-4.1288). People preferring both types of therapy were younger than those preferring only GT and younger than those preferring neither (95% CI, -17.9803–-6.9804). People preferring neither were older than those preferring IT and older than those preferring both types of therapy. Analyses using age at diagnosis revealed that people preferring GT were older than those preferring IT (95% CI, 2.8742–11.4875) and older than those preferring both types of therapy (95% CI, 4.3789–13.9646). People preferring IT were younger than those preferring GT and younger than those preferring neither (95% CI, -13.7321–-3.9107). People preferring both were younger than those preferring GT and younger than those preferring neither (95% CI, -16.1545–-5.4701). People preferring neither type of therapy were older than those preferring IT and older than those preferring both types of therapy. Those preferring GT had significantly higher rates of “being a high school graduate or lower” and “currently undergoing chemotherapy.” They also exhibited significantly lower rates in “university graduate or higher” and “after chemotherapy.” Participants preferring IT were significantly more likely to be “working full-time” and “after chemotherapy,” and significantly less likely to be a “high school graduate or lower” and “currently undergoing chemotherapy.” Participants preferring both treatments were significantly more likely to be “university graduate or higher” and “work full-time” and significantly less likely to be a “high school graduate or below.” Participants not wanting to receive either treatment were significantly more likely to be “unemployed or a student” and significantly less likely to “work full-time.” Table 2 shows further details. 3.3. Frequency of MT, timing, duration, and cost Participants were asked about their preferences regarding frequency of MT, timing, duration, and cost. Table 3 outlines the most commonly selected items for each category. 3.3.1. Preferred frequency Regardless of preferred activity type, “once per chemotherapy course” was the most common response, chosen by 61.3% of those preferring GT, 60.7% preferring IT, and 60.7% preferring both therapy types. 3.3.2. Preferred timing Regardless of preferred activity type, the most common response was “on the day of chemotherapy,” chosen by 67.7% of those preferring GT, 62.5% preferring IT, and 64.2% preferring both therapy types. The reasons cited were “because I do not need to go to the hospital again,” “because it is not physically painful,” and “because it is psychologically painful.” 3.3.4. Preferred duration The most common responses for those preferring GT were “less than 30 minutes” and “31–60 minutes,” with 44.1% of respondents choosing either option. The most common response (56.8%) for those preferring IT was “less than 30 minutes.” The most common response (60.7%) for those preferring both therapy types was “31–60 minutes.” 3.3.5. Cost Regardless of preferred activity type, the most common response was “501–1000 yen,” chosen by 39.8% of those preferring GT, 31.8% preferring IT, and 32.8% preferring both therapy types, expecting to pay this amount (rate on July 22, 2025: 1 US dollar = 147.69 yen). 3.4. Expectations regarding MT Based on the author’s previous qualitative research [12], it was hypothesized that the current findings would differ depending on the participants’ preferred activity type. Accordingly, participants wanting to receive both types of therapy were asked to respond to questions regarding GT and IT separately, enabling examination of the differences between these two activity types (Table 4). Those preferring GT expressed significantly higher expectations to “interact with others,” “have an enjoyable time,” and “relieve stress,” and significantly lower expectations to “calm the mind.” Those preferring IT expressed significantly higher expectations to “calm the mind” and “alleviate physical side effects” and significantly lower expectations to “interact with others,” “have an enjoyable time,” “feel more energized,” and “experience increased motivation for treatment and hospital visits.” Those preferring both activity types exhibited significantly higher expectations to “interact with others” from GT. Regarding IT, they showed significantly higher expectations to “experience increased motivation for treatment and hospital visits” and significantly lower expectations to “interact with others” (p<0.05). 4. Discussion This quantitative study used a questionnaire created based on the results of a previous qualitative study [ 12 ] to clarify the specific MT preferences of PWBC undergoing chemotherapy in Japan. First, this study identified high demand for MT among these patients (80.9% of participants expressing interest) and some variation in their preferred activity type (GT, IT, or both types). Second, regarding therapy that would best meet the needs of patients undergoing chemotherapy, most participants preferred MT once per chemotherapy course or once every two courses, scheduled on the day of treatment, regardless of their preferred activity type. The preferred duration was less than 30 minutes or 31–60 minutes, and most were willing to pay 0–500 or 501–1,000 yen for the therapy. Third, participants’ expectations regarding MT differed by preferred activity type, with those preferring GT expecting to “interact with others” and “feel energized,” and those preferring IT expecting to “calm the mind” and “alleviate physical side effects.” 4.1. Preferences for MT among PWBC undergoing or previously having undergone perioperative chemotherapy This study found that 31.3% of participants (out of 300) preferred GT, 29.3% IT, and 20.3% both, with 80.9% indicating they would like to receive some form of MT. Comparisons with prior research are challenging due to sample heterogeneity, which focused on the need for MT. However, a USA study found that 85% of 65 patients with cancer expressed an interest in music interventions [ 15 ]—a finding similar to that reported in the current study. Moreover, a study in Germany reported that 40% of 486 patients with cancer (across various types and treatments) expressed an interest in MT [ 16 ]. Similarly, another study indicated that approximately 30% of patients with terminal cancer in hospice settings expressed interest in MT [ 17 ]. Gotay and Lau [ 18 ] surveyed patients with cancer from various ethnic groups regarding their experiences receiving psychological support and their level of interest in it. Their interest varied by country, and no apparent differences in preferences existed. Another study noted that health beliefs, cultural background, and healthcare experiences varied by ethnicity among patients with cancer, making it difficult to meet diverse preferences and causing frustration [ 19 ]. This highlights the need for further research on the preferences of patients with cancer from different contexts regarding MT. It also reinforces the importance of cultural sensitivity in caring for patients with cancer globally [ 20 ]. Additionally, studies have shown that younger patients experience more distress from cancer than older patients [ 15 ]. In the present study, those preferring IT and both therapy types tended to be significantly younger, both in current age and age at diagnosis. Notably, many participants who preferred only IT expected it to “calm the mind” and “alleviate physical side effects.” These findings suggest that patients who only preferred IT may have been experiencing strong psychological distress—consistent with prior research [ 15 ]. Past reviews have emphasized that young patients with cancer experience more intense physical and psychological pain, highlighting the need for care responsive to their specific needs. These reviews have also raised concerns regarding clinicians being insufficiently sensitive to the unique preferences and values of the younger generation [ 21 ]. To better meet these needs, we recommend reaching out for individualized support tailored to young patients’ circumstances. 4.2. MT intervention’s frequency, timing, duration, and cost To the authors’ knowledge, this is the first quantitative investigation aimed at clarifying specific preferences regarding MT interventions’ frequency, timing, duration, and cost among PWBC who prefer either GT or IT. The findings suggest that offering MT once every one to two chemotherapy courses on the treatment day for under 60 minutes and at less than 1,000 yen (= 6.77 US dollars ) may meet many patients’ preferences, regardless of activity type. A notable study reported that the influence of MT frequency on its effectiveness is unknown [ 1 ], while another study stated that a duration of “more than one month and less than two months” is most effective for improving the QoL of patients with cancer [ 3 ]. However, the literature also indicates that professionals face difficulties in designing an MT protocol that can be reasonably incorporated into different treatment schedules; some patients with cancer struggle to visit hospitals for MT, while others are reluctant to discuss their psychological distress with medical staff [ 10 , 22 ]. Nevertheless, considering the specific patient preferences identified in this study, responding flexibly to patient needs may make it feasible to incorporate more systematic MT into treatment schedules. 4.3. Expectations regarding MT Among those preferring GT and both therapy types, many participants expected to “interact with others”—consistent with previous qualitative research [ 12 ] and studies noting the “psychological effects of interaction and sharing of emotions between patients” in GT [ 23 ]. In GT for patients with cancer, sharing emotions with others who have the same illness helps them feel less unhappy and isolated while reassuring them their reactions are normal [ 24 ]. In this study sample, those preferring GT were significantly more likely than those preferring IT to view MT as an active and positive intervention, expecting to “have an enjoyable time” and “relieve stress.” Those preferring IT had significantly higher expectations to “calm the mind” and “alleviate physical side effects,” seeking relief from their psychological distress. These results may be due to the younger age of those preferring IT, who were more likely to experience psychological distress [ 15 ]. According to qualitative research, patients determine their preferences based on their relationship with music. Many patients enjoy singing, but those not good at singing dislike it. Patients with musical instrument experience prefer musical activities, and those with songwriting experience enjoy songwriting [ 12 ]. Various activities’ effectiveness has been studied, and by considering these results and tailoring activities to individual patients, it is possible to meet many patients’ preferences [ 25 , 26 ]. Studies highlight the importance of using MT to alleviate pain in patients with cancer, as it helps reduce psychological and physical problems [ 7 , 9 , 25 – 31 ]. These findings may help music therapists develop specific protocols for applying MT interventions to PWBC undergoing chemotherapy. 4.4. Limitations This study has certain limitations. All participants were female PWBC undergoing chemotherapy, and so caution is needed when generalizing the findings to male patients, patients with other cancer types, or those undergoing other treatment types. Moreover, the lack of samples from other cultures, countries, and healthcare systems also limits the findings’ applicability beyond the present study’s context. The profile of the participants and their expectations of MT differed according to their preferred type of activity. However, this study does not prove a causal relationship, and additional research is needed to examine these associations. Perioperative chemotherapy may have different effects on physical and psychological pain depending on the treatment regimen, and differences in treatment regimens may have influenced the results of this study. Due to the wide variety of treatment regimens used in this study, it was not possible to clarify the differences, and so further investigation is needed. 5. Conclusion This study explored the preferences of PWBC undergoing chemotherapy for MT, specifically regarding their expectations, timing, frequency, duration, cost, and activity types. The results indicate a high need and preference for MT among patients undergoing preoperative and postoperative chemotherapy in Japan, offering important insights for planning patient-centered care. The findings can assist healthcare professionals in selecting MT types that align with treatment schedules and patient needs in a clinical context in Japan. Furthermore, careful consideration is needed to ensure the therapy type aligns with patients’ expectations and effectively addresses their symptoms. This study’s results also support and clarify the previous qualitative studies’ hypotheses. Notably, despite the inclusion of an “other” category in the questionnaire—designed based on earlier qualitative findings—most participants selected predefined options, reinforcing the prior coding framework’s validity. Looking ahead, further research is needed to evaluate the effectiveness of interventions developed based on these preferences, examine how this preference framework applies to other populations, and explore the feasibility of implementing such interventions in clinical practice. Declarations Data availability statements The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request. Conflicts of Interest Kondo M and Okino S declare there are no conflicts of interest. Ms. Nakaya reports grants from 2024 Tokai University School of Medicine Research Aid, grants from 2023 Foundation for Promotion of Cancer Research in Japan—all unrelated to the submitted work. Dr. Yamasato reports grants from Grants-in-Aid for Scientific Research—all unrelated to the submitted work. Dr. Kitano reports grants and personal fees from Shiseido Co., Ltd., personal fees from Eisai Co., Ltd., personal fees from Dai-ichi Sankyo Co., Ltd., personal fees from Chugai Pharma Co., Ltd., personal fees from Pfizer Japan Inc., personal fees from Eli Lilly and Company, and personal fees from AstraZeneca KK Co., Ltd. — all unrelated to the submitted work. Dr. Tsuda reports personal compensation from Daiichi Sankyo Co., Ltd., MSD K.K., Shionogi & Co., Ltd., and Ono Pharmaceutical Co., Ltd.—all unrelated to the submitted work. Dr. Tokuhara reports personal fees from Otsuka Pharmaceutical Factory, Inc., personal fees from Eisai Co., Ltd., and personal fees from Specialist Doctors Inc.—all unrelated to the submitted work. Dr. Yamamoto reports grants and personal fees from Otsuka Pharmaceutical Co., Ltd., grants and personal fees from Shionogi & Co., Ltd, grants and personal fees from Eisai Co., Ltd., personal fees from Mitsubishi Tanabe Pharma Corporation, personal fees from Sumitomo Dainippon Pharma Co., Ltd., personal fees from Meiji Seika Pharma Co., Ltd., personal fees from Pfizer Japan Inc., personal fees from Eli Lilly and Company, personal fees from EA Pharma Co., Ltd., personal fees from Merck Sharp & Dohme, personal fees from Viatris Inc., personal fees from Astellas Pharma Co., Ltd., grants from Grants-in-Aid for Scientific Research (C), grants from medical corporation, Tanzawa hospital, grants from medical corporation, Seishinkai, grants from medical corporation, Kishikai, grants from medical corporation, Kensuikai, grants from medical corporation, Seikikai, grants from medical corporation, Kyogetsukai, grants from medical corporation, Aokisuejiroukinenkai, grants from Social welfare corporation and Social Business department of Houanji—all unrelated to the submitted work. Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Research Ethics and Informed Consent The study was approved by the Research Ethics Committee of the Tokai School of Medicine (approval number: 20R245) and the Research Ethics Committee of St. Luke’s International Hospital (approval number: 21R006). References Bradt J, Dileo C, Myers-Coffman K, Biondo J (2021) Music interventions for improving psychological and physical outcomes in people with cancer. Cochrane Database Syst Rev 10(10):CD006911. https://doi.org/10.1002/14651858.CD006911.pub4 Gramaglia C, Gambaro E, Vecchi C, et al. (2019) Outcomes of music therapy interventions in cancer patients-a review of the literature. Crit Rev Oncol Hematol 138:241–254. https://doi.org/10.1016/j.critrevonc.2019.04.004 Li Y, Xing X, Shi X, et al. (2020) The effectiveness of music therapy for patients with cancer: a systematic review and meta-analysis. J Adv Nurs 76(5):1111-1123. https://doi.org/10.1111/jan.14313 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492 Tsaras K, Papathanasiou IV, Mitsi D, et al. (2018) Assessment of depression and anxiety in breast cancer patients: prevalence and associated factors. Asian Pac J Cancer Prev 19(6):1661–1669. https://doi.org/10.22034/APJCP.2018.19.6.1661 Pilevarzadeh M, Amirshahi M, Afsargharehbagh R, Rafiemanesh H, Hashemi S-M, Balouchi A (2019) Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis. Breast Cancer Res Treat 176(3):519–533. https://doi.org/10.1007/s10549-019-05271-3 Chen S-C, Yeh M-L, Chang H-J, Lin M-F (2020) Music, heart rate variability, and symptom clusters: a comparative study. Support Care Cancer 28(1):351–360. https://doi.org/10.1007/s00520-019-04817-x Li X-M, Yan H, Zhou K-N, Dang S-N, Wang D-L, Zhang Y-P (2011) Effects of music therapy on pain among female breast cancer patients after radical mastectomy: results from a randomized controlled trial. Breast Cancer Res Treat 128(2):411–419. https://doi.org/10.1007/s10549-011-1533-z Zhou KN, Li XM, Yan H, Dang SN, Wang DL (2011) Effects of music therapy on depression and duration of hospital stay of breast cancer patients after radical mastectomy. Chin Med J (Engl) 124(15):2321–2327. Hanser SB, Bauer-Wu S, Kubicek L, et al. (2006) Effects of a music therapy intervention on quality of life and distress in women with metastatic breast cancer. J Soc Integr Oncol 4(3):116–124. https://doi.org/10.2310/7200.2006.014 O’Callaghan C, Hiscock R (2007) Interpretive subgroup analysis extends modified grounded theory research findings in oncologic music therapy. J Music Ther 44(3):256–281. https://doi.org/10.1093/jmt/44.3.256 Nakaya N, Yamasato A, Kondo M, Okino S, Kitano A, Yamamoto K. (2025) Music therapy preferences among breast cancer patients undergoing chemotherapy: a qualitative study. Music Ther Perspect 43(1):miae029. https://doi.org/10.1093/mtp/miae029 Charmaz K (2024) Constructing grounded theory: a practical guide through qualitative analysis, 2nd edn. Sage Publications, Los Angeles. Macromill. Questant. Accessed December 26, 2024. https://questant.jp/en/ Burns DS, Sledge RB, Fuller LA, Daggy JK, Monahan PO (2005) Cancer patients’ interest and preferences for music therapy. J Music Ther 42(3):185–199. https://doi.org/10.1093/jmt/42.3.185 Gencer D, Diel A, Klotzbach K, et al. (2019) Cancer patients and music: (prospective) results from a survey to evaluate potential complementary treatment approaches. J Cancer Res Clin Oncol 145(8):2141–2148. https://doi.org/10.1007/s00432-019-02959-3 Nakagami Y (1997) Hospice program and palliative medicine. Gan To Kagaku Ryoho 24(7):792–799. (in Japanese). Gotay CC, Lau AK (2002) Preferences for psychosocial interventions among newly diagnosed cancer patients from a multiethnic population. J Psychosoc Oncol 20(4):23–37. https://doi.org/10.1300/J077v20n04_02 Lim JW, Baik OM, Ashing-Giwa KT (2012) Cultural health beliefs and health behaviors in Asian American breast cancer survivors: a mixed-methods approach. Oncol Nurs Forum 39(4):388–397. https://doi.org/10.1188/12.ONF.388-397 Nolan TS, Alston A, Choto R, Moss KO (2021) Cultural humility: retraining and retooling nurses to provide equitable cancer care. Clin J Oncol Nurs 25(5):3–9. https://doi.org/10.1188/21.CJON.S1.3-9 Johnston EE, Rosenberg AR (2024) Palliative care in adolescents and young adults with cancer. J Clin Oncol 42(6):755–763. https://doi.org/10.1200/JCO.23.00709. Epub 2023 Oct 20. Holland JC, Andersen B, Breitbart WS, et al. (2013) Distress management. J Natl Compr Canc Netw 11(2):190–209. https://doi.org/10.6004/jnccn.2013.0027 Chen S-C, Chou C-C, Chang H-J, Lin M-F (2018) Comparison of group vs self-directed music interventions to reduce chemotherapy-related distress and cognitive appraisal: an exploratory study. Support Care Cancer 26(2):461–469. https://doi.org/10.1007/s00520-017-3850-1 Romito F, Lagattolla F, Costanzo C, Giotta F, Mattioli V (2013) Music therapy and emotional expression during chemotherapy. How do breast cancer patients feel? Eur J Integr Med 5(5):438–442. https://doi.org/10.1016/j.eujim.2013.04.001 Atkinson TM, Liou KT, Borten MA, et al. (2020) Association between music therapy techniques and patient-reported moderate to severe fatigue in hospitalized adults with cancer. JCO Oncol Pract 16(12):e1553–e1557. https://doi.org/10.1200/OP.20.00096 Bro ML, Johansen C, Vuust P, et al. (2019) Effects of live music during chemotherapy in lymphoma patients: a randomized, controlled, multi-center trial. Support Care Cancer 27(10):3887–3896. https://doi.org/10.1007/s00520-019-04666-8 Chlan LL (2000) Music therapy as a nursing intervention for patients supported by mechanical ventilation. AACN Clin Issues 11(1):128–138. https://doi.org/10.1097/00044067-200002000-00014 Clements-Cortés A (2017) Singing and vocal interventions in palliative and cancer care: music therapists’ perceptions of usage. J Music Ther 54(3):336–361. https://doi.org/10.1093/jmt/thx010 Good M, Chin CC (1998) The effects of Western music on postoperative pain in Taiwan. Kaohsiung J Med Sci 14(2):94–103. Lai H-L (2004) Music preference and relaxation in Taiwanese elderly people. Geriatr Nurs 25(5):286–291. https://doi.org/10.1016/j.gerinurse.2004.08.009 Park S, Williams RA, Lee D (2016) Effect of preferred music on agitation after traumatic brain injury. West J Nurs Res 38(4):394–410. https://doi.org/10.1177/0193945915593180 Tables Table 1. Profile of the participants Items Mean Age 52.2 (21-84) Age of morbidity 47.7 (20-77) Items Factors Number of People (%) Marital Status Married 214 (71.3%) Unmarried 61 (20.3％) Divorced 16 (5.3％) Widowed 9 (3.0％) Other 0 (0.0％) Education High school 146 (48.7％) University 70 (23.3％) Junior college 62 (20.7％) Graduate school 10 (3.3％) Junior high school 6 (2.0％) Other 6 (2.0％) Work Housewife 104 (35.7%) Full-time employee 98 (32.7%) Part-time employee 58 (19.3%) Without an occupation 32 (10.7%) Student 1 (0.3%) Other 7 (2.3%) Progress of Chemotherapy After treatment 180 (60.0%) During treatment 118 (39.3%) No response 2 (0.6%) Chemotherapy EC Protocol 144 (48.0%) Docetaxel 127 (42.3%) Paclitaxel 101 (33.7%) TC Protocol 31 (10.3%) AC Protocol 27 (9.0%) FEC Protocol 13 (4.3%) Capecitabine 12 (4.0%) DoseDence-AC Protocol 6 (2.0%) Other 46 (15.3%) No response 11 (3.7%) Abbreviations: EC=Epirubicin + Cyclophosphamide; AC=Doxorubicin + Cyclophosphamide; FEC=Fluorouracil + Epirubicin + Cyclophosphamide; TC=Docetaxel + Cyclophosphamide; Dose Dence-AC=Doxorubicin + Cyclophosphamide + Pegfilgrastim Table 2. Influence of participants’ sociodemographic and clinical characteristics on preferred activity type Variable Responses Group therapy Individual therapy Want to take both Do not want to take either p-value Number of participants who prefer the activity type 93 88 61 57 Current age ▲55.935 ▼48.818 ▼45.517 ▲58.086 p<0.001** Age at diagnosis ▲51.272 ▼44.091 ▼42.1 ▲53.069 p<0.001** Marital status Married 66 (71.0%) 58 (65.9%) 44 (72.1%) 46 (79.3%) n.s. Unmarried 16 (17.2%) 24 (27.3%) 13 (21.3%) 8 (13.8%) Divorced or widowed 11 (11.8%) 6 (6.8%) 4 (6.6%) 4 (6.9%) Educational level High school or lower ▲56 (60.2%) 44 (50.0%) ▼17 (27.9%) 35 (60.3%) p<0.001* University or higher ▼34 (36.6%) 43 (48.9%) ▲42 (68.9%) 22 (37.9%) Work Full-time employee 23 (24.7%) ▲37 (44.3%) ▲27 (44.3%) ▼10 (17.2%) p<0.05* Part-time employee 19 (20.4%) 17 (19.3%) 9 (14.8%) 13 (22.4%) Homemaker 39 (41.9%) 24 (27.3%) 20 (32.8%) 21 (36.2%) Unemployed or student 12 (12.9%) 6 (6.8%) 4 (6.6%) ▲11 (19.0%) Progress of chemotherapy Currently undergoing ▲46 (49.5%) ▼25 (28.4%) 22 (36.1%) 24 (41.4%) p<0.05* Completed ▼46 (49.5%) ▲62 (70.5%) 39 (63.9%) 33 (56.9%) * Pearson’s chi-squared test was applied to items other than current age and age at diagnosis, and a residual analysis was applied to items for which a significant difference was found. ** The Kruskal–Walis test was applied to current age and age at diagnosis, and a comparison of the groups was conducted because a significant difference was found. ▲Items that were significantly higher as a result of Tukey’s test and compared the groups. ▼Items that were significantly lower as a result of Tukey’s test and compared the groups. Table 3. Preferred frequency, timing, duration, and cost Group therapy Individual therapy Both therapies Items Factors Number of people (%) Number of people (%) Number of people (%) Frequency Once per course 51 (61.3%) 54 (61.4%) 37 (60.7%) Once per two courses 30 (32.3%) 24 (27.3%) 12 (19.7%) Twice or more per course 5 (5.4%) 5 (5.7%) 7 (11.5%) Once per three courses 2 (2.2%) 2 (2.3%) 3 (4.9%) Once per four courses 1 (1.1%) 0 (0.0%) 1 (1.6%) No response 4 (4.3%) 3 (3.4%) 1 (1.6%) Timing On the day of chemotherapy 63 (67.7%) 55 (62.5%) 26 (42.6%) Between 8 and 14 days after chemotherapy 14 (15.1%) 10 (11.4%) 8 (13.1%) Between 15 and 21 days after chemotherapy 9 (9.7%) 15 (17.0%) 16 (26.2%) 22 days or more after chemotherapy 2 (2.2%) 3 (3.4%) 3 (4.9%) Within 7 days of the day after chemotherapy 1 (1.1%) 4 (4.5%) 7 (11.5%) Any time is fine 1 (1.1%) 1 (1.1%) 1 (1.6%) No answer 3 (3.2%) 0 (0.0%) 0 (0.0%) Reasons for requesting this timing Because I do not need to go to the hospital again 47 (50.5%) 41 (46.6%) 21 (34.4%) Because it is not physically painful 40 (43.0%) 42 (47.7%) 26 (42.6%) Because it is psychologically painful 8 (8.6%) 17 (19.3%) 9 (14.8%) Because it is physically painful 3 (3.2%) 5 (5.7%) 9 (14.8%) Because it is not psychologically painful 2 (2.2%) 7 (8.0%) 2 (3.3%) Because I think it will motivate me to get treatment 2 (2.2%) 12 (13.6%) 17 (27.9%) Other 4 (4.3%) 5 (5.7%) 1 (1.6%) No response 2 (2.2%) 0 (0.0%) 1 (1.6%) Duration Less than 30 minutes 41 (44.1%) 50 (56.8%) 21 (34.4%) 31 to 60 minutes 41 (44.1%) 32 (36.4%) 37 (60.7%) 61 to 120 minutes 6 (6.5%) 4 (4.5%) 1 (1.6%) More than 121 minutes 3 (3.2%) 2 (2.3%) 2 (3.3%) No response 2 (2.2%) 0 (0.0%) 0 (0.0%) Cost 501-1000 yen 37 (39.8%) 28 (31.8%) 20 (32.8%) 0-500 yen 29 (31.9%) 26 (29.5%) 14 (23.0%) 1001-2000 yen 10 (10.8%) 12 (13.6%) 10 (16.4%) 2001-3000 yen 10 (10.8%) 9 (10.2%) 11 (18.0%) 3001-5000 yen 4 (4.3%) 5 (5.7%) 1 (1.6%) 5001 yen or more 0 (0.0%) 2 (2.3%) 1 (1.6%) Cite Share Download PDF Status: Published Journal Publication published 03 Sep, 2025 Read the published version in International Journal of Clinical Oncology → Version 1 posted Editorial decision: Accept 23 Aug, 2025 Reviewers agreed at journal 31 Jul, 2025 Reviewers invited by journal 31 Jul, 2025 Editor assigned by journal 28 Jul, 2025 First submitted to journal 27 Jul, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-6695158","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":493523144,"identity":"4de507d0-a166-46b5-841e-4d4167170c8e","order_by":0,"name":"Nanami Nakaya","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA4UlEQVRIiWNgGAWjYFACNghlf//xASAlIUO8FoYDaQkgLTykaMkxAFGEtci3tyU+YGy7w8DYcObzqxs1FjwM7IePbsCnxeDMscMGjG3PGJgZe7dZ5xwDOownLe0GXi0S6W0SDGcOM7Ax824zzmEDapHgMcOrRX7+c4gWHjaeZ8Y5/4jQwnCD7ZgEQ8VhoEIe5se5bURoMTiTlmyQUHGYx0CCzYw5t08CaBsBv8i3HzN88MHgsJyBBPPjzznf6uT42Q8fw+8wEEiARAebBIjDhl8tKmD+QIrqUTAKRsEoGDkAAAvBQObRlcsgAAAAAElFTkSuQmCC","orcid":"https://orcid.org/0009-0004-3711-2118","institution":"Tokai University School of Medicine Graduate School of Medicine: Tokai Daigaku Igakubu Daigakuin Igaku Kenkyuka","correspondingAuthor":true,"prefix":"","firstName":"Nanami","middleName":"","lastName":"Nakaya","suffix":""},{"id":493523145,"identity":"5dedcfd6-b18d-4d13-b0b7-ba24cfc25c78","order_by":1,"name":"Ami Yamasato","email":"","orcid":"","institution":"Department of Psychiatry, Tokai University","correspondingAuthor":false,"prefix":"","firstName":"Ami","middleName":"","lastName":"Yamasato","suffix":""},{"id":493523146,"identity":"76b53f7c-dbaf-4063-8cef-4a1cc85c9355","order_by":2,"name":"Mayu Kondo","email":"","orcid":"","institution":"Department of Art, School Humanities \u0026 Culture, Tokai University","correspondingAuthor":false,"prefix":"","firstName":"Mayu","middleName":"","lastName":"Kondo","suffix":""},{"id":493523147,"identity":"61189a2a-f952-47b9-be9b-29c1a829b908","order_by":3,"name":"Shigeki Okino","email":"","orcid":"","institution":"Department of Art, School Humanities \u0026 Culture, Tokai University","correspondingAuthor":false,"prefix":"","firstName":"Shigeki","middleName":"","lastName":"Okino","suffix":""},{"id":493523148,"identity":"3b418fb7-8561-4909-866a-79f25a90e019","order_by":4,"name":"Atsuko Kitano","email":"","orcid":"","institution":"Department of Oncology, St. Luke's International Hospital","correspondingAuthor":false,"prefix":"","firstName":"Atsuko","middleName":"","lastName":"Kitano","suffix":""},{"id":493523149,"identity":"4c39e825-20f0-4127-ae65-ca326bc66ab6","order_by":5,"name":"Banri Tsuda","email":"","orcid":"","institution":"Department of Palliative Medicine, Tokai University","correspondingAuthor":false,"prefix":"","firstName":"Banri","middleName":"","lastName":"Tsuda","suffix":""},{"id":493523150,"identity":"5362089e-78cd-4680-97fc-e631accab965","order_by":6,"name":"Makoto Tokuhara","email":"","orcid":"","institution":"Department of Palliative Medicine, Tokai University","correspondingAuthor":false,"prefix":"","firstName":"Makoto","middleName":"","lastName":"Tokuhara","suffix":""},{"id":493523151,"identity":"237cdfee-78b8-453d-9f8f-956fee2002cc","order_by":7,"name":"Kenji Yamamoto","email":"","orcid":"","institution":"Department of Psychiatry, Tokai University","correspondingAuthor":false,"prefix":"","firstName":"Kenji","middleName":"","lastName":"Yamamoto","suffix":""}],"badges":[],"createdAt":"2025-05-19 05:17:59","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-6695158/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-6695158/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1007/s10147-025-02872-5","type":"published","date":"2025-09-03T15:58:01+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":90828116,"identity":"6f26099a-c115-454f-80e0-5d3f8731aa28","added_by":"auto","created_at":"2025-09-08 16:05:50","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1027496,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-6695158/v1/8704dbae-047c-4e98-a4a1-51138d58f54d.pdf"}],"financialInterests":"","formattedTitle":"Music Therapy Preferences Among Breast Cancer Patients Undergoing Perioperative Chemotherapy: From Qualitative Insight to Quantitative Evidence","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003eThe effectiveness of music therapy (MT) in patients with cancer has recently been reported, with meta-analyses and reviews conducted to clarify this effectiveness showing that such therapy and music-based interventions improve quality of life (QoL), anxiety, depression, and pain in patients with cancer [\u003cspan additionalcitationids=\"CR2\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. These studies also illustrate that MT and music-based interventions for this population may be effective in various treatment situations (e.g., before and after tests and surgery, during chemotherapy, and during palliative care), regardless of cancer type. Furthermore, this therapy may be useful for alleviating physical problems (e.g., pain), low life quality, and psychological issues (e.g., depression and anxiety) caused by cancer and its treatment.\u003c/p\u003e\u003cp\u003eBreast cancer is the most common cancer among women, accounting for 11.6% of all cancers worldwide [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. Patients with breast cancer (PWBC) are also at high risk of developing psychological disorders, e.g., depression and anxiety [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e], with a global depression prevalence among these patients of 32.2% [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. Some studies have reported that receptive MT significantly improves symptoms of pain, depression, fatigue, and sleep disorders [\u003cspan additionalcitationids=\"CR8\" citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. However, these studies often developed the MT protocol based on the music therapist\u0026rsquo;s experience rather than on a standardized format, considering participants, techniques, or duration of therapy.\u003c/p\u003e\u003cp\u003eThe consensus is that MT for patients with cancer should be tailored to the type of cancer afflicting the patient and their unique treatment situation (e.g., whether before or after tests and surgery or during chemotherapy and palliative care) [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. However, limited research has examined patient preferences. One study reported that 88% of patients with cancer undergoing treatment for three months expressed positive opinions on MT [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. Before the authors\u0026rsquo; initial qualitative study [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e], no studies in Japan had examined the preferences or opinions of patients with cancer regarding MT or the preferences of PWBC undergoing treatment or MT protocols.\u003c/p\u003e\u003cp\u003eTo address the gap in patient-informed MT design, we conducted a qualitative study to clarify the preferences of Japanese PWBC regarding MT during chemotherapy [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. The results were classified into three categories: relationship to music, pain from treatment, and preferences for MT. The analysis showed that patients undergoing chemotherapy determine their MT preferences based on their own musical experiences and physical and psychological pain. Furthermore, subcategories were created for patients\u0026rsquo; expectations regarding the content, frequency, duration, and cost\u0026mdash;among other factors\u0026mdash;of MT. An overview of the MT expectations of PWBC undergoing perioperative chemotherapy was presented. Subsequently, to determine whether the content of the authors\u0026rsquo; prior qualitative research represents the opinions of most PWBC undergoing perioperative chemotherapy, a larger-scale quantitative study was deemed necessary. Thus, building on prior qualitative findings, this study aimed to quantitatively examine MT preferences\u0026mdash;across dimensions such as activity type, timing, frequency, duration, cost, and therapeutic expectations\u0026mdash;among PWBC undergoing perioperative chemotherapy in Japan.\u003c/p\u003e"},{"header":"2. Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e\u003ch2\u003e2.1. \u003cem\u003eParticipants\u003c/em\u003e\u003c/h2\u003e\u003cp\u003eParticipants were adults who 1) had been diagnosed with primary breast cancer and were undergoing or had undergone perioperative chemotherapy at University Hospital A or Hospital B, or 2) were involved in Breast Cancer Support Community C, had been diagnosed with primary breast cancer, and were undergoing or had undergone perioperative chemotherapy. All participants read the explanatory document and provided informed consent.\u003c/p\u003e\u003cp\u003eThe doctors in charge at University Hospital A and Hospital B recruited participants by distributing flyers to viable candidates. These candidates accessed and answered the questionnaire online using the URL and QR code provided on the flyer. Breast Cancer Support Community C was similarly asked to include the questionnaire URL and QR code in a recruitment-focused email and distribute it to potential participants.\u003c/p\u003e\u003cp\u003eThe questionnaire was developed using subcategories obtained from the prior qualitative study, with the corresponding codes used as multiple-choice options. It was validated by experts, including music therapists, psychiatrists, breast oncologists, and palliative care physicians. The application period spanned September 2021\u0026ndash;November 2021.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec4\" class=\"Section2\"\u003e\u003ch2\u003e2.2. \u003cem\u003eData collection\u003c/em\u003e\u003c/h2\u003e\u003cp\u003eThe questionnaire was created based on the results of a qualitative study [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e] conducted using Charmaz\u0026rsquo;s [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e] constructivist grounded theory approach. The multiple-choice questionnaire collected data on respondents\u0026rsquo; current age, age at diagnosis, marital status, educational level, occupation, current treatment status, and chemotherapy type, as well as their preferred MT format (group or IT), expectations, frequency, timing, duration, and cost. Data were collected online using Questant [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]\u0026mdash;a self-administered questionnaire tool provided by Macromill, Inc.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec5\" class=\"Section2\"\u003e\u003ch2\u003e2.3. \u003cem\u003eAnalysis\u003c/em\u003e\u003c/h2\u003e\u003cp\u003eDescriptive statistics were utilized to analyze the data collected using the questionnaire. Pearson\u0026rsquo;s chi-squared test and the Kruskal\u0026ndash;Walis test were employed to investigate the relationship between participants\u0026rsquo; sociodemographics, clinical characteristics, and preferred activity type, with p\u0026thinsp;\u0026lt;\u0026thinsp;0.05 expressing statistical significance in both tests. A residual analysis was conducted for items with a significant difference in Pearson\u0026rsquo;s chi-squared test; for items with a significant difference in the Kruskal\u0026ndash;Walis test (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05), the groups were compared. A Pearson\u0026rsquo;s chi-squared test (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05) was conducted to assess differences in expectations between group and IT when both were desired. Items with a significant difference underwent a residual analysis. SPSS version 26 was used for all statistical procedures.\u003c/p\u003e\u003cp\u003eTo uphold the findings\u0026rsquo; reliability and validity, the research team (comprising psychiatrists, music therapists, breast oncology specialists, and musicology experts) met once a week to review data collection methods, share data, and confirm analysis methods and results.\u003c/p\u003e\u003c/div\u003e"},{"header":"3. Results","content":"\u003cp\u003e3.1. \u003cem\u003eParticipants\u0026rsquo; sociodemographic and clinical characteristics\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eThe study included 300 participants aged 21\u0026ndash;84 (M=52.2 years, SD=12.4), with an age at diagnosis of 20\u0026ndash;77 (M=47.7 years, SD=11.9). Table 1 shows participants\u0026rsquo; sociodemographic and clinical characteristics.\u003c/p\u003e\n\u003cp\u003e3.2. \u003cem\u003eFactors associated with preferred activity type\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eRegarding preferred activity type, 93 participants (31.0%) chose \u0026ldquo;group therapy\u0026rdquo; (GT), 88 (29.3%) \u0026ldquo;individual therapy\u0026rdquo; (IT), 61 (20.3%) \u0026ldquo;I want to receive both,\u0026rdquo; and 57 (19.0%) \u0026ldquo;I don\u0026rsquo;t want to receive either.\u0026rdquo; In total, 80.9% of participants expressed interest in receiving some form of MT. Among those preferring neither (multiple responses were allowed), 26.3% answered \u0026ldquo;because it is physically painful,\u0026rdquo; meaning they are in too much pain to consider receiving therapy, and 22.8% responded \u0026ldquo;because it is not psychologically painful\u0026rdquo; and therefore do not need any pain-relieving therapies.\u003c/p\u003e\n\u003cp\u003eAnalyses using participants\u0026rsquo; current age revealed that people preferring GT were older than those preferring IT (95% CI, 2.6852\u0026ndash;11.5480) and older than those preferring both (95% CI, 5.4864\u0026ndash;15.3498). People preferring IT were younger than those preferring GT and younger than those preferring neither (95% CI, -14.243\u0026ndash;-4.1288). People preferring both types of therapy were younger than those preferring only GT and younger than those preferring neither (95% CI, -17.9803\u0026ndash;-6.9804). People preferring neither were older than those preferring IT and older than those preferring both types of therapy.\u003c/p\u003e\n\u003cp\u003eAnalyses using age at diagnosis revealed that people preferring GT were older than those preferring IT (95% CI, 2.8742\u0026ndash;11.4875) and older than those preferring both types of therapy (95% CI, 4.3789\u0026ndash;13.9646). People preferring IT were younger than those preferring GT and younger than those preferring neither (95% CI, -13.7321\u0026ndash;-3.9107). People preferring both were younger than those preferring GT and younger than those preferring neither (95% CI, -16.1545\u0026ndash;-5.4701). People preferring neither type of therapy were older than those preferring IT and older than those preferring both types of therapy.\u003c/p\u003e\n\u003cp\u003eThose preferring GT had significantly higher rates of \u0026ldquo;being a high school graduate or lower\u0026rdquo; and \u0026ldquo;currently undergoing chemotherapy.\u0026rdquo; They also exhibited significantly lower rates in \u0026ldquo;university graduate or higher\u0026rdquo; and \u0026ldquo;after chemotherapy.\u0026rdquo; Participants preferring IT were significantly more likely to be \u0026ldquo;working full-time\u0026rdquo; and \u0026ldquo;after chemotherapy,\u0026rdquo; and significantly less likely to be a \u0026ldquo;high school graduate or lower\u0026rdquo; and \u0026ldquo;currently undergoing chemotherapy.\u0026rdquo; Participants preferring both treatments were significantly more likely to be \u0026ldquo;university graduate or higher\u0026rdquo; and \u0026ldquo;work full-time\u0026rdquo; and significantly less likely to be a \u0026ldquo;high school graduate or below.\u0026rdquo; Participants not wanting to receive either treatment were significantly more likely to be \u0026ldquo;unemployed or a student\u0026rdquo; and significantly less likely to \u0026ldquo;work full-time.\u0026rdquo; Table 2 shows further details.\u003c/p\u003e\n\u003cp\u003e3.3. \u003cem\u003eFrequency of MT, timing, duration, and cost\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eParticipants were asked about their preferences regarding frequency of MT, timing, duration, and cost. Table 3 outlines the most commonly selected items for each category.\u003c/p\u003e\n\u003cp\u003e3.3.1. Preferred frequency\u003c/p\u003e\n\u003cp\u003eRegardless of preferred activity type, \u0026ldquo;once per chemotherapy course\u0026rdquo; was the most common response, chosen by 61.3% of those preferring GT, 60.7% preferring IT, and 60.7% preferring both therapy types.\u003c/p\u003e\n\u003cp\u003e3.3.2. Preferred timing\u003c/p\u003e\n\u003cp\u003eRegardless of preferred activity type, the most common response was \u0026ldquo;on the day of chemotherapy,\u0026rdquo; chosen by 67.7% of those preferring GT, 62.5% preferring IT, and 64.2% preferring both therapy types. The reasons cited were \u0026ldquo;because I do not need to go to the hospital again,\u0026rdquo; \u0026ldquo;because it is not physically painful,\u0026rdquo; and \u0026ldquo;because it is psychologically painful.\u0026rdquo;\u003c/p\u003e\n\u003cp\u003e3.3.4. Preferred duration\u003c/p\u003e\n\u003cp\u003eThe most common responses for those preferring GT were \u0026ldquo;less than 30 minutes\u0026rdquo; and \u0026ldquo;31\u0026ndash;60 minutes,\u0026rdquo; with 44.1% of respondents choosing either option. The most common response (56.8%) for those preferring IT was \u0026ldquo;less than 30 minutes.\u0026rdquo; The most common response (60.7%) for those preferring both therapy types was \u0026ldquo;31\u0026ndash;60 minutes.\u0026rdquo;\u003c/p\u003e\n\u003cp\u003e3.3.5. Cost\u003c/p\u003e\n\u003cp\u003eRegardless of preferred activity type, the most common response was \u0026ldquo;501\u0026ndash;1000 yen,\u0026rdquo; chosen by 39.8% of those preferring GT, 31.8% preferring IT, and 32.8% preferring both therapy types, expecting to pay this amount (rate on July 22, 2025: 1 US dollar = 147.69 yen).\u003c/p\u003e\n\u003cp\u003e3.4. \u003cem\u003eExpectations regarding MT\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eBased on the author\u0026rsquo;s previous qualitative research [12], it was hypothesized that the current findings would differ depending on the participants\u0026rsquo; preferred activity type. Accordingly, participants wanting to receive both types of therapy were asked to respond to questions regarding GT and IT separately, enabling examination of the differences between these two activity types (Table 4).\u003c/p\u003e\n\u003cp\u003eThose preferring GT expressed significantly higher expectations to \u0026ldquo;interact with others,\u0026rdquo; \u0026ldquo;have an enjoyable time,\u0026rdquo; and \u0026ldquo;relieve stress,\u0026rdquo; and significantly lower expectations to \u0026ldquo;calm the mind.\u0026rdquo; Those preferring IT expressed significantly higher expectations to \u0026ldquo;calm the mind\u0026rdquo; and \u0026ldquo;alleviate physical side effects\u0026rdquo; and significantly lower expectations to \u0026ldquo;interact with others,\u0026rdquo; \u0026ldquo;have an enjoyable time,\u0026rdquo; \u0026ldquo;feel more energized,\u0026rdquo; and \u0026ldquo;experience increased motivation for treatment and hospital visits.\u0026rdquo;\u003c/p\u003e\n\u003cp\u003eThose preferring both activity types exhibited significantly higher expectations to \u0026ldquo;interact with others\u0026rdquo; from GT. Regarding IT, they showed significantly higher expectations to \u0026ldquo;experience increased motivation for treatment and hospital visits\u0026rdquo; and significantly lower expectations to \u0026ldquo;interact with others\u0026rdquo; (p\u0026lt;0.05).\u003c/p\u003e"},{"header":"4. Discussion","content":"\u003cp\u003eThis quantitative study used a questionnaire created based on the results of a previous qualitative study [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e] to clarify the specific MT preferences of PWBC undergoing chemotherapy in Japan. First, this study identified high demand for MT among these patients (80.9% of participants expressing interest) and some variation in their preferred activity type (GT, IT, or both types). Second, regarding therapy that would best meet the needs of patients undergoing chemotherapy, most participants preferred MT once per chemotherapy course or once every two courses, scheduled on the day of treatment, regardless of their preferred activity type. The preferred duration was less than 30 minutes or 31\u0026ndash;60 minutes, and most were willing to pay 0\u0026ndash;500 or 501\u0026ndash;1,000 yen for the therapy. Third, participants\u0026rsquo; expectations regarding MT differed by preferred activity type, with those preferring GT expecting to \u0026ldquo;interact with others\u0026rdquo; and \u0026ldquo;feel energized,\u0026rdquo; and those preferring IT expecting to \u0026ldquo;calm the mind\u0026rdquo; and \u0026ldquo;alleviate physical side effects.\u0026rdquo;\u003c/p\u003e\u003cdiv id=\"Sec16\" class=\"Section2\"\u003e\u003ch2\u003e4.1. \u003cem\u003ePreferences for MT among PWBC undergoing or previously having undergone perioperative chemotherapy\u003c/em\u003e\u003c/h2\u003e\u003cp\u003eThis study found that 31.3% of participants (out of 300) preferred GT, 29.3% IT, and 20.3% both, with 80.9% indicating they would like to receive some form of MT. Comparisons with prior research are challenging due to sample heterogeneity, which focused on the need for MT. However, a USA study found that 85% of 65 patients with cancer expressed an interest in music interventions [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]\u0026mdash;a finding similar to that reported in the current study. Moreover, a study in Germany reported that 40% of 486 patients with cancer (across various types and treatments) expressed an interest in MT [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Similarly, another study indicated that approximately 30% of patients with terminal cancer in hospice settings expressed interest in MT [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eGotay and Lau [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e] surveyed patients with cancer from various ethnic groups regarding their experiences receiving psychological support and their level of interest in it. Their interest varied by country, and no apparent differences in preferences existed. Another study noted that health beliefs, cultural background, and healthcare experiences varied by ethnicity among patients with cancer, making it difficult to meet diverse preferences and causing frustration [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. This highlights the need for further research on the preferences of patients with cancer from different contexts regarding MT. It also reinforces the importance of cultural sensitivity in caring for patients with cancer globally [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eAdditionally, studies have shown that younger patients experience more distress from cancer than older patients [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. In the present study, those preferring IT and both therapy types tended to be significantly younger, both in current age and age at diagnosis. Notably, many participants who preferred only IT expected it to \u0026ldquo;calm the mind\u0026rdquo; and \u0026ldquo;alleviate physical side effects.\u0026rdquo; These findings suggest that patients who only preferred IT may have been experiencing strong psychological distress\u0026mdash;consistent with prior research [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. Past reviews have emphasized that young patients with cancer experience more intense physical and psychological pain, highlighting the need for care responsive to their specific needs. These reviews have also raised concerns regarding clinicians being insufficiently sensitive to the unique preferences and values of the younger generation [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]. To better meet these needs, we recommend reaching out for individualized support tailored to young patients\u0026rsquo; circumstances.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec17\" class=\"Section2\"\u003e\u003ch2\u003e4.2. \u003cem\u003eMT intervention\u0026rsquo;s frequency, timing, duration, and cost\u003c/em\u003e\u003c/h2\u003e\u003cp\u003eTo the authors\u0026rsquo; knowledge, this is the first quantitative investigation aimed at clarifying specific preferences regarding MT interventions\u0026rsquo; frequency, timing, duration, and cost among PWBC who prefer either GT or IT. The findings suggest that offering MT once every one to two chemotherapy courses on the treatment day for under 60 minutes and at less than 1,000 yen (=\u0026thinsp;6.77 US dollars ) may meet many patients\u0026rsquo; preferences, regardless of activity type.\u003c/p\u003e\u003cp\u003eA notable study reported that the influence of MT frequency on its effectiveness is unknown [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e], while another study stated that a duration of \u0026ldquo;more than one month and less than two months\u0026rdquo; is most effective for improving the QoL of patients with cancer [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. However, the literature also indicates that professionals face difficulties in designing an MT protocol that can be reasonably incorporated into different treatment schedules; some patients with cancer struggle to visit hospitals for MT, while others are reluctant to discuss their psychological distress with medical staff [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. Nevertheless, considering the specific patient preferences identified in this study, responding flexibly to patient needs may make it feasible to incorporate more systematic MT into treatment schedules.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec18\" class=\"Section2\"\u003e\u003ch2\u003e4.3. \u003cem\u003eExpectations regarding MT\u003c/em\u003e\u003c/h2\u003e\u003cp\u003eAmong those preferring GT and both therapy types, many participants expected to \u0026ldquo;interact with others\u0026rdquo;\u0026mdash;consistent with previous qualitative research [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e] and studies noting the \u0026ldquo;psychological effects of interaction and sharing of emotions between patients\u0026rdquo; in GT [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. In GT for patients with cancer, sharing emotions with others who have the same illness helps them feel less unhappy and isolated while reassuring them their reactions are normal [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eIn this study sample, those preferring GT were significantly more likely than those preferring IT to view MT as an active and positive intervention, expecting to \u0026ldquo;have an enjoyable time\u0026rdquo; and \u0026ldquo;relieve stress.\u0026rdquo; Those preferring IT had significantly higher expectations to \u0026ldquo;calm the mind\u0026rdquo; and \u0026ldquo;alleviate physical side effects,\u0026rdquo; seeking relief from their psychological distress. These results may be due to the younger age of those preferring IT, who were more likely to experience psychological distress [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. According to qualitative research, patients determine their preferences based on their relationship with music. Many patients enjoy singing, but those not good at singing dislike it. Patients with musical instrument experience prefer musical activities, and those with songwriting experience enjoy songwriting [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. Various activities\u0026rsquo; effectiveness has been studied, and by considering these results and tailoring activities to individual patients, it is possible to meet many patients\u0026rsquo; preferences [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e, \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]. Studies highlight the importance of using MT to alleviate pain in patients with cancer, as it helps reduce psychological and physical problems [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan additionalcitationids=\"CR26 CR27 CR28 CR29 CR30\" citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e]. These findings may help music therapists develop specific protocols for applying MT interventions to PWBC undergoing chemotherapy.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec19\" class=\"Section2\"\u003e\u003ch2\u003e4.4. \u003cem\u003eLimitations\u003c/em\u003e\u003c/h2\u003e\u003cp\u003eThis study has certain limitations. All participants were female PWBC undergoing chemotherapy, and so caution is needed when generalizing the findings to male patients, patients with other cancer types, or those undergoing other treatment types. Moreover, the lack of samples from other cultures, countries, and healthcare systems also limits the findings\u0026rsquo; applicability beyond the present study\u0026rsquo;s context.\u003c/p\u003e\u003cp\u003eThe profile of the participants and their expectations of MT differed according to their preferred type of activity. However, this study does not prove a causal relationship, and additional research is needed to examine these associations.\u003c/p\u003e\u003cp\u003ePerioperative chemotherapy may have different effects on physical and psychological pain depending on the treatment regimen, and differences in treatment regimens may have influenced the results of this study. Due to the wide variety of treatment regimens used in this study, it was not possible to clarify the differences, and so further investigation is needed.\u003c/p\u003e\u003c/div\u003e"},{"header":"5. Conclusion","content":"\u003cp\u003eThis study explored the preferences of PWBC undergoing chemotherapy for MT, specifically regarding their expectations, timing, frequency, duration, cost, and activity types. The results indicate a high need and preference for MT among patients undergoing preoperative and postoperative chemotherapy in Japan, offering important insights for planning patient-centered care. The findings can assist healthcare professionals in selecting MT types that align with treatment schedules and patient needs in a clinical context in Japan. Furthermore, careful consideration is needed to ensure the therapy type aligns with patients\u0026rsquo; expectations and effectively addresses their symptoms. This study\u0026rsquo;s results also support and clarify the previous qualitative studies\u0026rsquo; hypotheses. Notably, despite the inclusion of an \u0026ldquo;other\u0026rdquo; category in the questionnaire\u0026mdash;designed based on earlier qualitative findings\u0026mdash;most participants selected predefined options, reinforcing the prior coding framework\u0026rsquo;s validity. Looking ahead, further research is needed to evaluate the effectiveness of interventions developed based on these preferences, examine how this preference framework applies to other populations, and explore the feasibility of implementing such interventions in clinical practice.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eData availability statements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflicts of Interest\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eKondo M and Okino S declare there are no conflicts of interest.\u003c/p\u003e\n\u003cp\u003eMs. Nakaya reports grants from 2024 Tokai University School of Medicine Research Aid, grants from 2023 Foundation for Promotion of Cancer Research in Japan\u0026mdash;all unrelated to the submitted work.\u003c/p\u003e\n\u003cp\u003eDr. Yamasato reports grants from Grants-in-Aid for Scientific Research\u0026mdash;all unrelated to the submitted work.\u003c/p\u003e\n\u003cp\u003eDr. Kitano reports grants and personal fees from Shiseido Co., Ltd., personal fees from Eisai Co., Ltd., personal fees from Dai-ichi Sankyo Co., Ltd., personal fees from Chugai Pharma Co., Ltd., personal fees from Pfizer Japan Inc., personal fees from Eli Lilly and Company, and personal fees from AstraZeneca KK Co., Ltd. \u0026mdash; all unrelated to the submitted work.\u003c/p\u003e\n\u003cp\u003eDr. Tsuda reports personal compensation from Daiichi Sankyo Co., Ltd., MSD K.K., Shionogi \u0026amp; Co., Ltd., and Ono Pharmaceutical Co., Ltd.\u0026mdash;all unrelated to the submitted work.\u003c/p\u003e\n\u003cp\u003eDr. Tokuhara reports personal fees from Otsuka Pharmaceutical Factory, Inc., personal fees from Eisai Co., Ltd., and personal fees from Specialist Doctors Inc.\u0026mdash;all unrelated to the submitted work.\u003c/p\u003e\n\u003cp\u003eDr. Yamamoto reports grants and personal fees from Otsuka Pharmaceutical Co., Ltd., grants and personal fees from Shionogi \u0026amp; Co., Ltd, grants and personal fees from Eisai Co., Ltd., personal fees from Mitsubishi Tanabe Pharma Corporation, personal fees from Sumitomo Dainippon Pharma Co., Ltd., personal fees from Meiji Seika Pharma Co., Ltd., personal fees from Pfizer Japan Inc., personal fees from Eli Lilly and Company, personal fees from EA Pharma Co., Ltd., personal fees from Merck Sharp \u0026amp; Dohme, personal fees from Viatris Inc., personal fees from Astellas Pharma Co., Ltd., grants from Grants-in-Aid for Scientific Research (C), grants from medical corporation, Tanzawa hospital, grants from medical corporation, Seishinkai, grants from medical corporation, Kishikai, grants from medical corporation, Kensuikai, grants from medical corporation, Seikikai, grants from medical corporation, Kyogetsukai, grants from medical corporation, Aokisuejiroukinenkai, grants from Social welfare corporation and Social Business department of Houanji\u0026mdash;all unrelated to the submitted work.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResearch Ethics and Informed Consent\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe study was approved by the Research Ethics Committee of the Tokai School of Medicine (approval number: 20R245) and the Research Ethics Committee of St. Luke\u0026rsquo;s International Hospital (approval number: 21R006).\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eBradt J, Dileo C, Myers-Coffman K, Biondo J (2021) Music interventions for improving psychological and physical outcomes in people with cancer. Cochrane Database Syst Rev 10(10):CD006911. https://doi.org/10.1002/14651858.CD006911.pub4\u003c/li\u003e\n\u003cli\u003eGramaglia C, Gambaro E, Vecchi C, et al. (2019) Outcomes of music therapy interventions in cancer patients-a review of the literature. Crit Rev Oncol Hematol 138:241\u0026ndash;254. https://doi.org/10.1016/j.critrevonc.2019.04.004\u003c/li\u003e\n\u003cli\u003eLi Y, Xing X, Shi X, et al. (2020) The effectiveness of music therapy for patients with cancer: a systematic review and meta-analysis. J Adv Nurs 76(5):1111-1123. https://doi.org/10.1111/jan.14313\u003c/li\u003e\n\u003cli\u003eBray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u0026ndash;424. https://doi.org/10.3322/caac.21492\u003c/li\u003e\n\u003cli\u003eTsaras K, Papathanasiou IV, Mitsi D, et al. (2018) Assessment of depression and anxiety in breast cancer patients: prevalence and associated factors. Asian Pac J Cancer Prev 19(6):1661\u0026ndash;1669. https://doi.org/10.22034/APJCP.2018.19.6.1661\u003c/li\u003e\n\u003cli\u003ePilevarzadeh M, Amirshahi M, Afsargharehbagh R, Rafiemanesh H, Hashemi S-M, Balouchi A (2019) Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis. Breast Cancer Res Treat 176(3):519\u0026ndash;533. https://doi.org/10.1007/s10549-019-05271-3\u003c/li\u003e\n\u003cli\u003eChen S-C, Yeh M-L, Chang H-J, Lin M-F (2020) Music, heart rate variability, and symptom clusters: a comparative study. Support Care Cancer 28(1):351\u0026ndash;360. https://doi.org/10.1007/s00520-019-04817-x\u003c/li\u003e\n\u003cli\u003eLi X-M, Yan H, Zhou K-N, Dang S-N, Wang D-L, Zhang Y-P (2011) Effects of music therapy on pain among female breast cancer patients after radical mastectomy: results from a randomized controlled trial. Breast Cancer Res Treat 128(2):411\u0026ndash;419. https://doi.org/10.1007/s10549-011-1533-z\u003c/li\u003e\n\u003cli\u003eZhou KN, Li XM, Yan H, Dang SN, Wang DL (2011) Effects of music therapy on depression and duration of hospital stay of breast cancer patients after radical mastectomy. Chin Med J (Engl) 124(15):2321\u0026ndash;2327.\u003c/li\u003e\n\u003cli\u003eHanser SB, Bauer-Wu S, Kubicek L, et al. (2006) Effects of a music therapy intervention on quality of life and distress in women with metastatic breast cancer. J Soc Integr Oncol 4(3):116\u0026ndash;124. https://doi.org/10.2310/7200.2006.014\u003c/li\u003e\n\u003cli\u003eO\u0026rsquo;Callaghan C, Hiscock R (2007) Interpretive subgroup analysis extends modified grounded theory research findings in oncologic music therapy. J Music Ther 44(3):256\u0026ndash;281. https://doi.org/10.1093/jmt/44.3.256\u003c/li\u003e\n\u003cli\u003eNakaya N, Yamasato A, Kondo M, Okino S, Kitano A, Yamamoto K. (2025) Music therapy preferences among breast cancer patients undergoing chemotherapy: a qualitative study. Music Ther Perspect 43(1):miae029. https://doi.org/10.1093/mtp/miae029\u003c/li\u003e\n\u003cli\u003eCharmaz K (2024) Constructing grounded theory: a practical guide through qualitative analysis, 2nd edn. Sage Publications, Los Angeles.\u003c/li\u003e\n\u003cli\u003eMacromill. Questant. Accessed December 26, 2024. https://questant.jp/en/\u003c/li\u003e\n\u003cli\u003eBurns DS, Sledge RB, Fuller LA, Daggy JK, Monahan PO (2005) Cancer patients\u0026rsquo; interest and preferences for music therapy. J Music Ther 42(3):185\u0026ndash;199. https://doi.org/10.1093/jmt/42.3.185\u003c/li\u003e\n\u003cli\u003eGencer D, Diel A, Klotzbach K, et al. (2019) Cancer patients and music: (prospective) results from a survey to evaluate potential complementary treatment approaches. J Cancer Res Clin Oncol 145(8):2141\u0026ndash;2148. https://doi.org/10.1007/s00432-019-02959-3\u003c/li\u003e\n\u003cli\u003eNakagami Y (1997) Hospice program and palliative medicine. Gan To Kagaku Ryoho 24(7):792\u0026ndash;799. (in Japanese).\u003c/li\u003e\n\u003cli\u003eGotay CC, Lau AK (2002) Preferences for psychosocial interventions among newly diagnosed cancer patients from a multiethnic population. J Psychosoc Oncol 20(4):23\u0026ndash;37. https://doi.org/10.1300/J077v20n04_02\u003c/li\u003e\n\u003cli\u003eLim JW, Baik OM, Ashing-Giwa KT (2012) Cultural health beliefs and health behaviors in Asian American breast cancer survivors: a mixed-methods approach. Oncol Nurs Forum 39(4):388\u0026ndash;397. https://doi.org/10.1188/12.ONF.388-397\u003c/li\u003e\n\u003cli\u003eNolan TS, Alston A, Choto R, Moss KO (2021) Cultural humility: retraining and retooling nurses to provide equitable cancer care. Clin J Oncol Nurs 25(5):3\u0026ndash;9. https://doi.org/10.1188/21.CJON.S1.3-9\u003c/li\u003e\n\u003cli\u003eJohnston EE, Rosenberg AR (2024) Palliative care in adolescents and young adults with cancer. J Clin Oncol 42(6):755\u0026ndash;763. https://doi.org/10.1200/JCO.23.00709. Epub 2023 Oct 20.\u003c/li\u003e\n\u003cli\u003eHolland JC, Andersen B, Breitbart WS, et al. (2013) Distress management. J Natl Compr Canc Netw 11(2):190\u0026ndash;209. https://doi.org/10.6004/jnccn.2013.0027\u003c/li\u003e\n\u003cli\u003eChen S-C, Chou C-C, Chang H-J, Lin M-F (2018) Comparison of group vs self-directed music interventions to reduce chemotherapy-related distress and cognitive appraisal: an exploratory study. Support Care Cancer 26(2):461\u0026ndash;469. https://doi.org/10.1007/s00520-017-3850-1\u003c/li\u003e\n\u003cli\u003eRomito F, Lagattolla F, Costanzo C, Giotta F, Mattioli V (2013) Music therapy and emotional expression during chemotherapy. How do breast cancer patients feel? Eur J Integr Med 5(5):438\u0026ndash;442. https://doi.org/10.1016/j.eujim.2013.04.001\u003c/li\u003e\n\u003cli\u003eAtkinson TM, Liou KT, Borten MA, et al. (2020) Association between music therapy techniques and patient-reported moderate to severe fatigue in hospitalized adults with cancer. JCO Oncol Pract 16(12):e1553\u0026ndash;e1557. https://doi.org/10.1200/OP.20.00096\u003c/li\u003e\n\u003cli\u003eBro ML, Johansen C, Vuust P, et al. (2019) Effects of live music during chemotherapy in lymphoma patients: a randomized, controlled, multi-center trial. Support Care Cancer 27(10):3887\u0026ndash;3896. https://doi.org/10.1007/s00520-019-04666-8\u003c/li\u003e\n\u003cli\u003eChlan LL (2000) Music therapy as a nursing intervention for patients supported by mechanical ventilation. AACN Clin Issues 11(1):128\u0026ndash;138. https://doi.org/10.1097/00044067-200002000-00014\u003c/li\u003e\n\u003cli\u003eClements-Cort\u0026eacute;s A (2017) Singing and vocal interventions in palliative and cancer care: music therapists\u0026rsquo; perceptions of usage. J Music Ther 54(3):336\u0026ndash;361. https://doi.org/10.1093/jmt/thx010\u003c/li\u003e\n\u003cli\u003eGood M, Chin CC (1998) The effects of Western music on postoperative pain in Taiwan. Kaohsiung J Med Sci 14(2):94\u0026ndash;103.\u003c/li\u003e\n\u003cli\u003eLai H-L (2004) Music preference and relaxation in Taiwanese elderly people. Geriatr Nurs 25(5):286\u0026ndash;291. https://doi.org/10.1016/j.gerinurse.2004.08.009\u003c/li\u003e\n\u003cli\u003ePark S, Williams RA, Lee D (2016) Effect of preferred music on agitation after traumatic brain injury. West J Nurs Res 38(4):394\u0026ndash;410. https://doi.org/10.1177/0193945915593180\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Tables","content":"\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"567\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"7\" style=\"width: 97.7072%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTable 1. Profile of the participants\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"24\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 100px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eItems\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 123px;\"\u003e\n \u003cp\u003eMean\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17.6367%;\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"24\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 100px;\"\u003e\n \u003cp\u003eAge\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e52.2 (21-84)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"24\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 100px;\"\u003e\n \u003cp\u003eAge of morbidity\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e47.7 (20-77)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"20\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 100px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eItems\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eFactors\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e \u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNumber of People (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"20\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" rowspan=\"5\" style=\"width: 100px;\"\u003e\n \u003cp\u003eMarital Status\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eMarried\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e214 (71.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"20\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eUnmarried\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e61 (20.3％)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"20\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eDivorced\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e16 (5.3％)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"20\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eWidowed\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e9 (3.0％)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"20\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eOther\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e0 (0.0％)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"24\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" rowspan=\"6\" style=\"width: 100px;\"\u003e\n \u003cp\u003eEducation\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eHigh school\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e146 (48.7％)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"20\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eUniversity\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e70 (23.3％)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"20\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eJunior college\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e62 (20.7％)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"20\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eGraduate school\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e10 (3.3％)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"20\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eJunior high school\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e6 (2.0％)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"20\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eOther\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e6 (2.0％)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"24\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" rowspan=\"6\" style=\"width: 100px;\"\u003e\n \u003cp\u003eWork\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eHousewife\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e104 (35.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"20\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eFull-time employee\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e98 (32.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"20\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003ePart-time employee\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e58 (19.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"20\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"3\" style=\"width: 238px;\"\u003e\n \u003cp\u003eWithout an occupation\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e32 (10.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"24\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eStudent\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e1 (0.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"24\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eOther\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e7 (2.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"24\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" rowspan=\"3\" style=\"width: 100px;\"\u003e\n \u003cp\u003eProgress of\u0026nbsp;\u003cbr\u003e\u0026nbsp;Chemotherapy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eAfter treatment\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e180 (60.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"20\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eDuring treatment\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e118 (39.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"24\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eNo response\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e2 (0.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"24\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" rowspan=\"10\" style=\"width: 100px;\"\u003e\n \u003cp\u003eChemotherapy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eEC Protocol\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e144 (48.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"20\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eDocetaxel\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e127 (42.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"20\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003ePaclitaxel\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e101 (33.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"24\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eTC Protocol\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e31 (10.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"24\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eAC Protocol\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e27 (9.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"24\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eFEC Protocol\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e13 (4.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"24\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eCapecitabine\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e12 (4.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"24\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"3\" style=\"width: 238px;\"\u003e\n \u003cp\u003eDoseDence-AC Protocol\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e6 (2.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"24\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eOther\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e46 (15.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"24\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" style=\"width: 159px;\"\u003e\n \u003cp\u003eNo response\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 79px;\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 38.8007%;\"\u003e\n \u003cp\u003e11 (3.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"24\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"7\" rowspan=\"4\" valign=\"top\" style=\"width: 97.7072%;\"\u003e\n \u003cp\u003eAbbreviations: EC=Epirubicin + Cyclophosphamide; AC=Doxorubicin + Cyclophosphamide; FEC=Fluorouracil + Epirubicin + Cyclophosphamide;\u0026nbsp;\u003cbr\u003e\u0026nbsp;TC=Docetaxel + Cyclophosphamide; Dose Dence-AC=Doxorubicin + Cyclophosphamide + Pegfilgrastim\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"24\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd height=\"24\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd height=\"24\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 1.0582%;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd height=\"24\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 2.\u003c/strong\u003e \u003cstrong\u003eInfluence of participants\u0026rsquo; sociodemographic and clinical characteristics on preferred activity type\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eVariable\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eResponses\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGroup therapy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eIndividual therapy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eWant to take both\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eDo not want to take either\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 72px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep-value\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eNumber of participants who prefer the activity type\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e93\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e88\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e61\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e57\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 72px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eCurrent age\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e▲55.935\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e▼48.818\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e▼45.517\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e▲58.086\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 72px;\"\u003e\n \u003cp\u003ep\u0026lt;0.001**\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eAge at diagnosis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e▲51.272\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e▼44.091\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e▼42.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e▲53.069\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 72px;\"\u003e\n \u003cp\u003ep\u0026lt;0.001**\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"3\" style=\"width: 95px;\"\u003e\n \u003cp\u003eMarital status\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003eMarried\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e66 (71.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e58 (65.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e44 (72.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e46 (79.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 72px;\"\u003e\n \u003cp\u003en.s.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003eUnmarried\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e16 (17.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e24 (27.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e13 (21.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e8 (13.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 72px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003eDivorced or widowed\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e11 (11.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e6 (6.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e4 (6.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e4 (6.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 72px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 95px;\"\u003e\n \u003cp\u003eEducational level\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003eHigh school \u0026nbsp;or lower\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e▲56 (60.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e44 (50.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e▼17 (27.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e35 (60.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 72px;\"\u003e\n \u003cp\u003ep\u0026lt;0.001*\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003eUniversity or higher\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e▼34 (36.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e43 (48.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e▲42 (68.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e22 (37.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 72px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"4\" style=\"width: 95px;\"\u003e\n \u003cp\u003eWork\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003eFull-time employee\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e23 (24.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e▲37 (44.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e▲27 (44.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e▼10 (17.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 72px;\"\u003e\n \u003cp\u003ep\u0026lt;0.05*\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003ePart-time employee\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e19 (20.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e17 (19.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e9 (14.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e13 (22.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 72px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003eHomemaker\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e39 (41.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e24 (27.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e20 (32.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e21 (36.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 72px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003eUnemployed or student\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e12 (12.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e6 (6.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e4 (6.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e▲11 (19.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 72px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 95px;\"\u003e\n \u003cp\u003eProgress of\u0026nbsp;\u003cbr\u003e\u0026nbsp;chemotherapy\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003eCurrently undergoing\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e▲46 (49.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e▼25 (28.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e22 (36.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e24 (41.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 72px;\"\u003e\n \u003cp\u003ep\u0026lt;0.05*\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003eCompleted\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e▼46 (49.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e▲62 (70.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e39 (63.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e33 (56.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 72px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e* Pearson\u0026rsquo;s chi-squared test was applied to items other than current age and age at diagnosis, and a residual analysis was applied to items for which a significant difference was found.\u003c/p\u003e\n\u003cp\u003e** The Kruskal\u0026ndash;Walis test was applied to current age and age at diagnosis, and a comparison of the groups was conducted because a significant difference was found.\u003c/p\u003e\n\u003cp\u003e▲Items that were significantly higher as a result of Tukey\u0026rsquo;s test and compared the groups.\u003c/p\u003e\n\u003cp\u003e▼Items that were significantly lower as a result of Tukey\u0026rsquo;s test and compared the groups. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 3.\u003c/strong\u003e \u003cstrong\u003ePreferred frequency, timing, duration, and cost\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"99%\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGroup therapy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eIndividual therapy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eBoth therapies\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eItems\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eFactors\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNumber of people (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNumber of people (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNumber of people (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"6\" style=\"width: 20px;\"\u003e\n \u003cp\u003eFrequency\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eOnce per course\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e51 (61.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e54 (61.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e37 (60.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eOnce per two courses\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e30 (32.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e24 (27.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e12 (19.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eTwice or more per course\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e5 (5.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e5 (5.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e7 (11.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eOnce per three courses\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e2 (2.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e2 (2.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e3 (4.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eOnce per four courses\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e1 (1.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e1 (1.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eNo response\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e4 (4.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e3 (3.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e1 (1.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"7\" style=\"width: 20px;\"\u003e\n \u003cp\u003eTiming\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eOn the day of chemotherapy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e63 (67.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e55 (62.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e26 (42.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eBetween 8 and 14 days after chemotherapy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e14 (15.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e10 (11.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e8 (13.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eBetween 15 and 21 days after chemotherapy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e9 (9.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e15 (17.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e16 (26.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e22 days or more after chemotherapy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e2 (2.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e3 (3.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e3 (4.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eWithin 7 days of the day after chemotherapy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e1 (1.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e4 (4.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e7 (11.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eAny time is fine\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e1 (1.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e1 (1.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e1 (1.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eNo answer\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e3 (3.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"8\" style=\"width: 20px;\"\u003e\n \u003cp\u003eReasons for requesting\u0026nbsp;\u003cbr\u003e\u0026nbsp;this timing\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eBecause I do not need to go to the hospital again\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e47 (50.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e41 (46.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e21 (34.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eBecause it is not physically painful\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e40 (43.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e42 (47.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e26 (42.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eBecause it is psychologically painful\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e8 (8.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e17 (19.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e9 (14.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eBecause it is physically painful\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e3 (3.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e5 (5.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e9 (14.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eBecause it is not psychologically painful\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e2 (2.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e7 (8.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e2 (3.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eBecause I think it will motivate me to get treatment\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e2 (2.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e12 (13.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e17 (27.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eOther\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e4 (4.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e5 (5.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e1 (1.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eNo response\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e2 (2.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e1 (1.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"5\" style=\"width: 20px;\"\u003e\n \u003cp\u003eDuration\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eLess than 30 minutes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e41 (44.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e50 (56.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e21 (34.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e31 to 60 minutes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e41 (44.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e32 (36.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e37 (60.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e61 to 120 minutes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e6 (6.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e4 (4.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e1 (1.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eMore than 121 minutes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e3 (3.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e2 (2.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e2 (3.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eNo response\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e2 (2.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"6\" style=\"width: 20px;\"\u003e\n \u003cp\u003eCost\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e501-1000 yen\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e37 (39.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e28 (31.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e20 (32.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e0-500 yen\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e29 (31.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e26 (29.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e14 (23.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e1001-2000 yen\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e10 (10.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e12 (13.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e10 (16.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e2001-3000 yen\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e10 (10.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e9 (10.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e11 (18.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e3001-5000 yen\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e4 (4.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e5 (5.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e1 (1.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e5001 yen or more\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e0 (0.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e2 (2.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003e1 (1.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u0026nbsp;\u003cimg src=\"data:image/png;base64,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\" width=\"1170\" height=\"499\"\u003e\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"international-journal-of-clinical-oncology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"ijco","sideBox":"Learn more about [International Journal of Clinical Oncology](http://link.springer.com/journal/10147)","snPcode":"10147","submissionUrl":"https://www.editorialmanager.com/ijco/default2.aspx","title":"International Journal of Clinical Oncology","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"music therapy, palliative care, preference, request, breast cancer","lastPublishedDoi":"10.21203/rs.3.rs-6695158/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-6695158/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground\u003c/strong\u003e: Patients with breast cancer (PWBC) have a high risk of developing psychological disorders, and interventions should be implemented with care. For music therapy (MT)interventions to be more effective among these patients, providing therapeutic programs tailored to their preferences is desirable. Given the limited research on the preferences for MT of PWBC undergoing chemotherapy, we had previously conducted a qualitative study to clarify their preferences, yielding the formation of related hypotheses. Building upon these hypotheses, the current quantitative study aimed to clarify the specific preferences regarding MT of PWBC, who are undergoing chemotherapy, in Japan.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods\u003c/strong\u003e: This quantitative study’s questionnaire was created based on the results of our prior qualitative study and completed by 300 PWBC undergoing perioperative chemotherapy.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults\u003c/strong\u003e: (a) Of all participants, 80.9% wanted MT, and there was a relationship between preferred activity type and participants’ sociodemographic and clinical characteristics; (b) the expectations of participants regarding MT differed by preferred activity type; and (c) the participants’ preferences regarding the frequency, timing, duration, and cost of the MT intervention were constant regardless of the preferred activity type.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusions\u003c/strong\u003e: As patients’ specific preferences have been clarified, we conclude that professionals may be more well-positioned and informed to devise more appropriate and effective MT programs to be incorporated into the treatment schedules of PWBC who are undergoing chemotherapy, with vital quality-of-life implications resulting.\u003c/p\u003e","manuscriptTitle":"Music Therapy Preferences Among Breast Cancer Patients Undergoing Perioperative Chemotherapy: From Qualitative Insight to Quantitative Evidence","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-08-05 08:53:47","doi":"10.21203/rs.3.rs-6695158/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Accept","date":"2025-08-23T22:34:15+00:00","index":"","fulltext":""},{"type":"reviewerAgreed","content":"","date":"2025-07-31T09:15:21+00:00","index":0,"fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-07-31T05:51:57+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-07-29T02:12:35+00:00","index":"","fulltext":""},{"type":"submitted","content":"International Journal of Clinical Oncology","date":"2025-07-28T03:32:19+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"international-journal-of-clinical-oncology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"ijco","sideBox":"Learn more about [International Journal of Clinical Oncology](http://link.springer.com/journal/10147)","snPcode":"10147","submissionUrl":"https://www.editorialmanager.com/ijco/default2.aspx","title":"International Journal of Clinical Oncology","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"ce5300ef-6ab6-4cff-b2e3-afef25e610b7","owner":[],"postedDate":"August 5th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2025-09-08T16:04:43+00:00","versionOfRecord":{"articleIdentity":"rs-6695158","link":"https://doi.org/10.1007/s10147-025-02872-5","journal":{"identity":"international-journal-of-clinical-oncology","isVorOnly":false,"title":"International Journal of Clinical Oncology"},"publishedOn":"2025-09-03 15:58:01","publishedOnDateReadable":"September 3rd, 2025"},"versionCreatedAt":"2025-08-05 08:53:47","video":"","vorDoi":"10.1007/s10147-025-02872-5","vorDoiUrl":"https://doi.org/10.1007/s10147-025-02872-5","workflowStages":[]},"version":"v1","identity":"rs-6695158","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-6695158","identity":"rs-6695158","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}